CD274 and head and neck squamous cell carcinoma: The phase III EAGLE trial evaluated durvalumab, an α–PD-L1 monoclonal antibody, versus durvalumab plus tremelimumab (α–CTLA-4) versus SoC in patients with R/M HNSCC.